2 Under-the-Radar Stocks to Buy Heading Into 2026
Axsome Therapeutics (NASDAQ: AXSM) and (NASDAQ: EXEL) are hardly the best-known players in the large biotech industry. Thankfully, they don't need to be so to have excellent prospects. Both of these relatively small drugmakers have a lot going on that could lead to excellent financial results and strong stock market performances in the medium term. Let's dig deeper into Axsome Therapeutics and Exelixis and discuss why both biotechs are attractive buys heading into the new year.
Image source: Getty Images.
Axsome Therapeutics has performed well over the past year as it continues to make strong clinical and regulatory progress while generating steadily growing revenue. The company's Auvelity, approved for major depressive disorder in 2022, is making headway. It is currently its main growth driver. In the third quarter, Axsome Therapeutics' revenue increased by 63% year over year to $171 million.
Source Fool.com
Axsome Therapeutics Inc Stock
With 1 Sell predictions and 0 Buy predictions the community sentiment towards the Axsome Therapeutics Inc stock is not clear.
A potential of -40.59%, resulting from comparing the current price of 126.25 € with the target price of 75 € for Axsome Therapeutics Inc, shows the chance of incurring significant losses.
